Navigation Links
Experimental drug shows promise against head and neck cancer
Date:4/28/2009

April 28, 2009 (BRONX, NY) A laboratory study by researchers at Albert Einstein College of Medicine of Yeshiva University suggests that an anti-cancer compound studied for treating blood cancers may also help in treating cancers of the head and neck. The work is reported in the April 28th online edition of the Journal of Pathology.

Head and neck cancer refers to tumors in the mouth, throat, or larynx (voice box). Each year about 40,000 men and women develop head and neck cancer in the U.S., making it the country's sixth-most common type. Surgery, chemotherapy and/or radiation are the main treatment options but can cause serious side effects. Better treatments are needed, since only about half of patients with head and neck cancer survive for five or more years after diagnosis.

The Einstein study involved a new class of chemotherapy agents known as histone deacetylase (HDAC) inhibitors, which affect the availability of genes that are transcribed and translated into proteins. In many types of cancer, out-of-control cell growth results from certain genes that are either too active or not active enough in producing proteins. HDAC inhibitors appear to combat cancer by restoring the normal expression of key regulatory genes that control cell growth and survival.

The Einstein researchers focused on a particular HDAC inhibitor known as LBH589 that has already shown some success in clinical trials involving people with cancers of the blood. The researchers found that LBH589 succeeded in killing tumor cells that had been removed from head and neck cancer patients and grown in the laboratory.

"This report shows that an HDAC inhibitor is effective on head and neck cancer cell lines, and that is the first step toward use in humans," said Richard Smith, M.D., the lead clinician involved in the study. Dr. Smith is associate professor of clinical otorhinolaryngology-head & neck surgery and associate professor of surgery at Einstein and is also vice-chair of otorhinolaryngology-head & neck surgery at Einstein and Montefiore.

The researchers also identified a set of genes whose expression levels change in response to the HDAC inhibitorsa finding that may help doctors identify patients most likely to respond to the drug. Plans call for testing LBH589 on head and neck tumor cells from more patients so that the set of genes that respond to the drug can be more firmly established.

"We are performing studies in mice to confirm these laboratory results, which hopefully will progress to human clinical trials of LBH589 for the treatment of head and neck cancer," said Michael Prystowsky, M.D., Ph.D., chair and professor of pathology at Einstein and corresponding author of the article.


'/>"/>

Contact: Deirdre Branley
sciencenews@aecom.yu.edu
718-430-2923
Albert Einstein College of Medicine
Source:Eurekalert  

Related medicine news :

1. Experimental anti-cancer drug made from corn lillies kills brain tumor stem cells
2. Experimental Antidepressants Offer Faster Relief
3. Experimental drug shows promise in advanced kidney cancer
4. Experimental drug boosts survival in recurrent ovarian cancer
5. Experimental cancer pharmaceuticals under trial
6. Experimental Drug Fails Against Heart Failure
7. Experimental Drug Fights Prostate Cancer
8. Experimental technique at GUMC offers real-time analysis of breast cancer biopsies
9. Experimental Vaccine Halts Prostate Cancer in Mice
10. Experimental Biology 2008 Todays Research: Tomorrows Health, April 5-9
11. 52 minority scientists receive travel fellowships to Experimental Biology 2008
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental drug shows promise against head and neck cancer
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... Sharon Kleyne, ... Global Climate Change and Your Health on Voice of America, declared on her radio ... call attention to the fact that when these bullies attack leaders in corporate America, ...
(Date:12/7/2016)... ... December 07, 2016 , ... The Honolulu ... fully redesigned website, which launched October 17, 2016, features comprehensive information regarding a ... easy-to-navigate layout. Visitors and patients can discover the latest clinical dermatology treatments for ...
(Date:12/7/2016)... ... December 07, 2016 , ... Facial plastic surgeon, Dr. John D. Rachel ... a portion of proceeds to two local organizations: North Chicago Animal Control and Friends ... is a team of authorized and trained volunteers who support rescued animals held ...
(Date:12/7/2016)... ... 2016 , ... Delete® - Tattoo Removal and Laser Salon Offers Delightful Holiday ... Up To 33% Off Botox® and Juvederm® Products Now Through December 31, 2016 , ... Delightful Deals on Botox® and Juvederm® just in time for the holiday party ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... in Dallas, Texas, is condemning "scam operations" carried out by unethical locksmith companies ... these scam operations to a halt. According to Texas Premier Locksmith, these fraudulent ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... , Dec. 6, 2016   AlloSource , ... cellular, bone, skin and soft-tissue allografts for use ... Business Process Manager, for being named to the ... National Quality Award by the Commerce Department,s National ... organization,s commitment to process excellence. The Baldrige Award ...
(Date:12/6/2016)... , Dec. 6, 2016  BTL Aesthetics ... proving that its BTL Vanquish ME device was ... energy delivery to the targeted tissue. The result: ... 53% higher, with BTL Vanquish ME versus BTL ... our physician network and their patients with the ...
(Date:12/6/2016)... 2016 With opioids commonly used for pain management for ... market that has led to nationwide fatalities. The synthetic ... stronger than heroin or morphine, resulting in likelihood of addiction, abuse ... , , ... clinical operations, Behavioral Health for HMC HealthWorks, explained the opioid drug ...
Breaking Medicine Technology: